HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Direct Seller’s Advertising Mixing Boosting Health With Building Wealth Made Known To FTC

Executive Summary

Bulavita didn’t respond to Direct Selling Regulatory Council’s inquiry on claims its supplements could boost the immune system against COVID-19. In an assessment of the claims, the industry self-regulation group it would refer its questions to the FTC.

You may also be interested in...



Same Old Supplement Claim Violations Prompt US Regulators’ Action Under New COVID-19 Authority

FTC files complaint against Quickwork as first action under authority granted in the COVID-19 Consumer Protection Act. The enforcement came after the firm twice ingored warnings to discontinue claims its vitamin D and zinc supplements were equal to or more effective than current vaccines.

FTC Familiar With Direct Seller’s COVID-19 Claims Questioned By US Industry Self-Regulation Group

Direct Selling Self-Regulatory Council say after UWell Life didn’t respond to its requests to substantiate ad claims made online for Primocyn brand topicals, the council submitted to its concerns to the FTC.

CBBB Self-Regulatory Program Will ‘Elevate Reputation’ Of Direct Selling Industry

Similar to the National Advertising Division, the Direct Selling Self-Regulatory Council will provide a forum for competitive challenges in addition to routine monitoring of the direct-sales industry. Kelley Drye attorney John Villafranco predicts “greater self-regulatory focus on income misrepresentations and lavish lifestyle claims in the months ahead.”

Topics

UsernamePublicRestriction

Register

RS151250

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel